Member Info for Uncanny

Valju, l do like you with your candid opinion and l think you have some very valid points and quite right. But if they like their salaries as you purport, then why not find every inconceivable option to keep it running for another 5 - 10 years at least? Or just sell out? Do you believe the RNS updates going through CT or do you think the whole system is corrupt? Which begs the question why and how? RESULTS! Results = Shareholder value in time, albeit at not the best valuation for those that lost lots overtime, sad and irreversible now for many. I do sincerely commiserate as been there myself before with other investments. 2 years ago l invested and been a painful experience monetary wise, but think we may be surprised soon, time will tell. If our new investors are the 2 - 3mn sellers then they are not very aggressive and if Iwas going to take equity over loan l’d certainly make sure beforehand that l could sell in to a liquid market unless idiots. Personally l think there is madness in the method, plus our bod are not commercial people which is why its more to do with Kudos and they have outsourced the commercial aspect, not making millions its about but kudos not money bit as pro’s in the medical field want to make their name as doctors.

Tony, nail on the head! I think BoD waiting for something to burst before announcing AGM details, to please. AIMHO

Agree Dracula, but despite the dilution who can preempt the positive (hopefully IP)? Been here before as far back as Drew Scientific in the 90’s which was my first ever real punt on a stock option (when it existed) and turned £1000 in to £20,000. Things do turn around, but in spite of the dilution one has to be more realistic with VAL, so l forget anything past 5p unless we have the miracle of all RNS’s. 201 if successful could be game changer, lets wait and see shall we rather than speculate. 20-50 baggers do still exist on AIM. My biggest regret was buying ASOS at under 10p which was suggested by one of my more savvy investing friends in the 2000’s and again with Fevertree - who knew tonic would be so proitable!

Also, when ABO signed their JV with VAL and very possibly selling but we don’t know (but not very aggressive are they?) , are they so stupid as to go for conversion into shares rather than a straight loan agreement? Who is going to buy their stock? Look at the volumes thus far? If its all shxt and bust why do it and who is going to buy their stock? PI’s? No, we already have enough and higher averages unless an institutional buyer and then that begs the question - what do they see that we overlook in VAL? I think quite poignant facts.

True Mathsprof, thats what we are waiting for. The value thus far is the IP: Why go to P3 with 401 and 2 x LOI if not commercial? Why progress to CT with 201 if not positive? Why move from 301 PC to CT if not successful? Why enter a JV with ABO if ABO can’t see value on the horizon? Why go for stock over a fixed interest loan? Why buy FIT to support 101 if we are going to throw the towel in? Share price is shxt, but IMHO on the cuspe of something great even if its just 1 of the 4 compounds.

Roses, you are funny. Keep up the good work mate. Dilution? Yes lots of it, but we have turned the corner IMHO. Financing? Yes all in place for + 2 years Death spiral from RNS and .10p like some predict - hasn’t happened has it? Compounds? Yes all work so far unless RNS’s are lies which the BOD are accountable for if wrong or misleading.

3 facts:

So you’re not shorting because you can’t, but if you could you would. Your agenda is now confirmed. As said before, lets see what news comes to fruition in the near future. Since ABO RNS, it hasn’t exactly been the death spiral many have predicted in fact quite a lot of buying % wise. I think my 1p average b/e is attainable and much more. Remember 2 facts: 1. We have financing to get all the drugs to market now, if all commercial and those further off should be supoeted by the JV’s in place now, tba. 2. VAL have never over the years been in a position to complete P2 and go into P3. 401 now and 201 coming a little later. 3. All the compounds thus far have been positive. Like mentioned below, l sincerely think we will get a positive RNS pre AGM in whatever form that takes. IMHO, DYOR, GLA

Lets reserve judgement until we get the next bout of updates - GM stated “in the not too distant future” that we’d be getting updates on the compounds and JV’s.

Must have hit a nerve with someone

Good morning all I must thanks the kind soul that had me suspended for 3 days for disruptive and argumentative posting! LOL. 201 trial ends EOM and full analysis by Q3, but hoping for a quick one liner from GM in summertime to say how things have gone

I agree Freddy, l think SP has reached a floor now and just feels like things are going to turn. What do we have to look forward to: 101 JV details 401 JV details 401 - perhaps more Lol’s 201 higher dosing completion and update 301 preclinical results update 301 P1 start to commence 201 higher dose analysis 201 next stage news - JV / trade sale etc AGM Looks like the next 6 months are going to be very interesting times and as stated IMHO, l think as a P2 AIM junior bio we should be at a similar valuation to our peers which would be approx. 2.5p to 3p per share based on our shares in issue post ABO financing.

Yes, l’m averaging January. Cheers

No it means VAL were very fortuitous - fully financed by ABO who will commercialise 101. VAL get a free ride now, great news for VAL.

Sad for any company going in to admin like FIT Bio, but l reckon VAL couldn’t believe their luck when the IP was on offer! Great fit for VAL and ABO will fund it and sell it on.

You’re right Drac, just need to finance 301 and maybe not 201 if they accelerate and get a licensing deal / sell as mentioned in last RNS.

Well of course you would my flower.

Quite true BF. If the compounds work as suggested by RNS’s and presentations then things should turnaround nicely. If your so diluted down to 0.3%, then l hate to say it IMHO but its game over tbh, unless willing to take the risk and average down enormously - probably a no no l guess! Sad to hear that and l suppose l am very fortunate on a 1p B/E.

My reasoning? Our P2 peers are circa £20 to £25 million market cap which with the recent 213mn sub shares puts VAL at 894mn shares in issue which is equivalent to approx. 2.5 ps.

I sympathise BBD. My average is better but only after constantly averaging down. 201 could be a nice surprise as 401 was last time in Dec’17 when it 8 bagged in a few days. IMHO, the saving grace with 201 is that it has a much higher importance in the compound range so who knows? 101 and 301 update too, plus we still don’t know about 401 which could also help the SP. I think we can forget over 5p in the short to medium term unless we get some sort of blockbuster RNS, but l am hoping for 2-4p in the next 6 months if certain things fall in to place All IMHO and GLA.